HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. Co.'s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to improve immunogenicity and stability of the VLPs in solution. VLPs are self-assembling structures that mimic the certain and repetitive geometric features that characterize the surface of a live virus. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The HLVX average annual return since 2022 is shown above.
The Average Annual Return on the HLVX average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HLVX average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HLVX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|